Close Menu

NEW YORK – Boston-based NanoView Biosciences said today that it has signed an exclusive agreement with Alfatest, headquartered in Rome, to distribute its ExoView platform in Italy.

The research-use-only ExoView platform is an antibody labeling and imaging-based extracellular vesicle detection system that provides size analysis, vesicle count, phenotyping, and biomarker colocalization. According to the company, it requires minimal sample input, no sample prep or purification, and can be used directly with complex biological samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.